Entera Bio Ltd. (ENTX)
2.84
-0.17
(-5.65%)
USD |
NASDAQ |
Sep 09, 16:00
2.84
0.00 (0.00%)
After-Hours: 17:07
Entera Bio EPS Diluted (Quarterly) : -0.1449 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1449 |
| March 31, 2026 | -0.0734 |
| December 31, 2025 | -0.0653 |
| September 30, 2025 | -0.068 |
| June 30, 2025 | -0.0567 |
| March 31, 2025 | -0.0592 |
| December 31, 2024 | -0.0607 |
| September 30, 2024 | -0.0802 |
| June 30, 2024 | -0.0578 |
| March 31, 2024 | -0.0549 |
| December 31, 2023 | -0.0672 |
| September 30, 2023 | -0.0826 |
| June 30, 2023 | -0.0807 |
| March 31, 2023 | -0.076 |
| December 31, 2022 | -0.1053 |
| September 30, 2022 | -0.1065 |
| June 30, 2022 | -0.1106 |
| March 31, 2022 | -0.1314 |
| December 31, 2021 | 0.1707 |
| September 30, 2021 | -0.1121 |
| June 30, 2021 | -0.1043 |
| March 31, 2021 | -0.1049 |
| December 31, 2020 | -0.1214 |
| Date | Value |
|---|---|
| September 30, 2020 | -0.0886 |
| June 30, 2020 | -0.1749 |
| March 31, 2020 | -0.1617 |
| December 31, 2019 | -0.2628 |
| September 30, 2019 | -0.2486 |
| June 30, 2019 | -0.1163 |
| March 31, 2019 | -0.2613 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | -0.3265 |
| September 30, 2017 | -0.40 |
| June 30, 2017 | -0.30 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| BioLineRx Ltd. | -0.6957 |
| XTL Biopharmaceuticals Ltd. | -- |
| Kamada Ltd. | 0.1605 |
| Can-Fite BioPharma Ltd. | -- |
| Galmed Pharmaceuticals Ltd. | -2.860 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -7.312M |
| Total Expenses (Quarterly) | 7.312M |
| Enterprise Value | 130.36M |
| Earnings Yield | -12.38% |
| Normalized Earnings Yield | -12.38 |